ADOPTIVE CELL THERAPY OF SOFT TISSUE SARCOMAS USING AUTOLOGOUS TUMOR VACCINATION

使用自体肿瘤疫苗接种软组织肉瘤的过继细胞疗法

• 批准号: 6297203
• 负责人: VERNON K. SONDAK
• 金额: $ 0.02万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6297203
• 关键词: T cell receptor; T lymphocyte; autologous transplantation; clinical research; colony stimulating factor; human subject; human therapy evaluation; immunosuppression; neoplasm /cancer immunotherapy; neoplasm /cancer vaccine; passive immunization; sarcoma; transfection; tumor antigens

It has recently been shown that human sarcomas express tumor-associated antigens potentially capable of being recognized by the immune system. However, the weakness of these antigens and/or the presence of tumor-induced suppression results in an ineffective immune response in sarcoma patients. We propose to generate vaccine-primed T cells for the immunotherapy of stage IV sarcoma patients utilizing methods derived from extensive preclinical studies. These studies have demonstrated that lymph node cells (lymphocytes) from lymph nodes draining the site of a tumor vaccination harbor T cells which can develop specific antitumor reactivity against poorly immunogenic tumors after in vitro activation. The studies proposed herein will yield important insights into the requirements for eliciting T cell responses against sarcoma-associated tumor antigens.

最近已经显示，人类肉瘤表达与免疫系统识别能够识别的肿瘤相关的抗原。但是，这些抗原的弱点和/或肿瘤诱导的抑制作用导致肉瘤患者的免疫反应无效。 我们建议通过广泛的临床前研究得出的方法生成疫苗生化的T细胞，以进行IV期肉瘤患者的免疫疗法。 这些研究表明，淋巴结淋巴结的淋巴结细胞（淋巴细胞）会排出肿瘤疫苗接种部位的T细胞，这些细胞可以在体外激活后针对不良免疫原性肿瘤产生特定的抗肿瘤反应性。本文提出的研究将对引起与肉瘤相关的肿瘤抗原的T细胞反应的要求产生重要的见解。